PRESS RELEASE published on 05/21/2025 at 18:00, 1 year 5 months ago A new milestone towards the market launch of AXPERA: EU Member States unanimously vote in favour of the approval of Amoéba's biocontrol active substance Amoéba receives unanimous approval from EU Member States for low-risk biocontrol substance based on amoebae lysate, a milestone for AXPERA solution market launch in Europe from 2026 AMOEBA Biocontrol EU Approval AXPERA Low-risk Substance
BRIEF published on 05/20/2025 at 19:05, 1 year 5 months ago Amoéba Renforce son Conseil d'Administration avec Charlotte Franceries AMOEBA Conseil D'administration Cosmétique GreenTech Charlotte Franceries
BRIEF published on 05/20/2025 at 19:05, 1 year 5 months ago Amoéba Strengthens its Board of Directors with Charlotte Franceries AMOEBA Board Of Directors GreenTech Cosmetic Charlotte Franceries
PRESS RELEASE published on 05/20/2025 at 19:00, 1 year 5 months ago Amoéba annonce l'arrivée au sein de son Conseil d'administration de Charlotte Franceries, actrice majeure du monde de la cosmétique et de la communication Amoéba annonce la candidature de Charlotte Franceries au poste d'Administratrice, apportant son expertise du secteur cosmétique. Une décision importante pour le Conseil d'Administration AMOEBA Conseil D'administration Cosmétique Expertise Charlotte Franceries
PRESS RELEASE published on 05/20/2025 at 19:00, 1 year 5 months ago Amoéba announces the nomination of Charlotte Franceries, a leading figure in the cosmetics and communications industry, to its Board of Directors Amoéba announces the proposed appointment of Charlotte Franceries as a member of its Board of Directors, bringing extensive expertise from the cosmetics industry AMOEBA Board Of Directors Appointment Cosmetics Industry Charlotte Franceries
BRIEF published on 05/12/2025 at 18:05, 1 year 5 months ago Amoéba et Koppert en phase finale avant le lancement d'AXPERA Biocontrôle Innovation Agricole Autorisations AXPERA Lancement Amoéba Koppert
BRIEF published on 05/12/2025 at 18:05, 1 year 5 months ago Amoéba and Koppert in final phase before the launch of AXPERA Biocontrol Agricultural Innovation Authorizations AXPERA Launch Amoéba Koppert
PRESS RELEASE published on 05/12/2025 at 18:00, 1 year 5 months ago Amoéba et Koppert continuent de préparer le lancement commercial d'AXPERA, le produit de biocontrôle développé par Amoéba Amoéba et Koppert poursuivent la préparation du lancement commercial d'AXPERA, solution de biocontrôle innovante. Autorisations obtenues en France et aux Pays-Bas AMOEBA Biocontrôle Autorisations AXPERA Koppert
PRESS RELEASE published on 05/12/2025 at 18:00, 1 year 5 months ago Amoéba and Koppert continue to prepare the commercial launch of AXPERA, the biocontrol product developed by Amoéba. Amoéba to continue preparing for commercial launch of biocontrol solution AXPERA with Koppert, following successful authorisations. Company aims to meet market expectations for innovative biocontrol solutions AMOEBA Biocontrol Commercial Launch AXPERA Koppert
BRIEF published on 05/06/2025 at 08:05, 1 year 5 months ago Amoéba obtient une dérogation aux Pays-Bas pour AXPERA AMOEBA Biocontrôle Pays-Bas Autorisation AXPERA
Published on 11/04/2026 at 23:10, 2 hours 34 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 2 hours 44 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 3 hours 29 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 3 hours 39 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 00:02, 1 hour 41 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 6 hours 2 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 18 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 7 hours ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 7 hours 38 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 18:00, 7 hours 43 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 7 hours 43 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 8 hours ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026